Given the suggested role of hepatic ASK1 ablation in the pathogenesis of NAFLD, we evaluated the therapeutic effects of pharmacological ASK1 inhibition. Here, MAP3K5 is linked to metabolic dysfunction-associated steatotic liver disease.